Zinc as an adjunctive therapy in patients with schizophrenia:A randomized double-blind placebo controlled study

Central Institute of psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1.Male and female inpatients satisfying the ICD 10 - DCR [1993] criteria of Schizophrenia
•2.Age group of 18-60 years.
•3.Illness duration of minimum 2 years.
•4.PANSS total score of minimum 80.
•5.Those who give informed consent for participating in the study.

•1.Any other major comorbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
•2.Significant current/ past medical or neurological illness including severe hepatic disease and history of severe head injury.
•3.Known hypersensitivity to Cap. Zinc Sulphate or any of its components.
•4.Patients who had received ECT in the last 6 months.
•5.Comorbid medical illness known to affect zinc levels including acute or chronic inflammatory
•disorder and neurological disorder.
•6.Patient on multivitamin supplementation.

发起方